Future analyses could incorporate longitudinal plasma markers of Aβ and tau, as recent data showed faster increase in plasma pTau181 levels over time in APOE4 carriers compared with noncarriers in the PREVENT-AD cohort (Yakoub et al., 2023). Here, MAPT is linked to Alzheimer disease.